Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c

The proportion of patients achieving the 26-week endpoint was 37.4% with dulaglutide compared to 10.3% with insulin glargine.

• Dulaglutide showed a higher probability of reaching the fasting serum glucose target without hypoglycemia at weeks 4 and 8.
• Odds ratios indicated that patients on dulaglutide were 1.78 times more likely to meet the fasting glucose target at week 4 and 1.69 times more likely at week 8 compared to those on insulin glargine.
• The 26-week endpoint included achieving a glycated hemoglobin level below 7.0% or a reduction of at least 1.0%, without hypoglycemia or weight gain.
• Dulaglutide's favorable efficacy-to-safety profile was evident early and sustained over 6 months.

AI simplified